Epic Sciences’ research in prostate cancer presented at the 2013 ASCO Genitourinary Cancers Symposium.
Epic Sciences, Inc.(“Epic”), a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla. The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).
The poster will be presented during General Poster Session A: Prostate Cancer on Thursday, February 14 from 11:45 am to 1:15 pm EST in Gatlin Ballroom B. Additional presentation details are as follows:
- Poster Title: Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).
- Authors: Elizabeth Punnoose, Eric Tucker, Dena Marrinucci, Edith Szafer-Glusman, Lukas Amler, Hartmut Koeppen, Premal Patel, Gerhardt Attard, Johann De Bono
- Poster Number: D17
- About: Circulating Tumor Cells (CTCs)
CTCs are cells that escape from solid tumors, enter the bloodstream where they travel and eventually cause cancer metastasis. Today, solid cancers are first detected by invasive biopsies, which cannot be used repeatedly and may be ineffective in understanding metastatic risk, disease progression, treatment effectiveness and recurrence identification. A blood test that can accurately detect and profile biomarkers on CTCs is easy to conduct frequently and should be able to provide essential, real-time information about disease status to tailor treatments to a patient’s specific cancer and response.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org,+1.858.344.8091